Cell and Gene Therapy, Industry
November 17, 2023
Via: PharmaphorumCapivasertib has been approved as Truqap for use in combination with AZ’s oestrogen receptor antagonist Faslodex (fulvestrant) for adults with hormone receptor (HR)-positive and HER2-negative locally advanced or metastatic breast cancer, but only if they also have PIK3CA, AKT1, or […]
July 11, 2024
July 11, 2024
July 19, 2024